Daxiang Biotech joined global leaders in Microphysiological Systems (MPS) research and innovation at MPS World Summit 2026, where the company showcased its integrated Organoids-on-Chips platform and engaged with researchers, industry partners, and innovators from around the world.

Held in Washington, D.C. from May 26–29, the summit brought together more than 1,500 scientists, industry professionals, regulators, and innovators from 35 countries. With over 100 exhibitors, 166 speakers, and 556 scientific posters, the event served as a global forum for scientific exchange and collaboration across the rapidly evolving MPS ecosystem.

The summit highlighted the growing role of human-relevant models in drug discovery and safety assessment, reflecting increasing momentum behind the adoption of New Approach Methodologies (NAMs) and continued advances in organoid and organ-on-chip technologies.

Showcasing an Integrated Organoids-on-Chips Ecosystem

At Booth #509, Daxiang Biotech presented its integrated Organoids-on-Chips ecosystem, featuring:

- IBAC® Organoids-on-Chips Platform, including four specialized chip systems designed for diverse research applications

- Human organoid and disease models for drug discovery, disease research, and translational studies

- Research instruments and automation solutions that support efficient and standardized experimental workflows

Together, these solutions reflect Daxiang's approach to integrating organoid biology, microengineering, AI, and automation to support more predictive, scalable, and human-relevant drug discovery workflows.

Key Industry Trends

Several themes emerged throughout the summit across scientific, regulatory, and industry discussions:

- Continued growth in the adoption of New Approach Methodologies (NAMs)

- Increasing regulatory support for human-relevant models from agencies such as the FDA

- Expanding use of AI and automation to improve efficiency, scalability, and data quality

- Accelerating commercialization of organoid and organ-on-chip technologies

- Growing emphasis on standardization, reproducibility, and cross-industry collaboration

These developments reflect a broader shift toward more predictive, efficient, and human-relevant approaches to biomedical research and pharmaceutical development.

Building Global Connections

During the summit, Daxiang Biotech's leadership and international business development team met with pharmaceutical companies, biotechnology innovators, academic researchers, technology providers, and industry organizations from around the world. These discussions provided valuable opportunities to exchange perspectives on emerging industry trends, explore potential collaborations, and strengthen relationships across the global MPS community.

Visitors expressed particular interest in Daxiang's integrated approach to combining organoids, organ-on-chip technologies, AI, and automation within a unified platform for drug discovery and biomedical research.

Looking Ahead

As interest in organoids, organ-on-chip technologies, and NAMs continues to grow worldwide, Daxiang Biotech remains committed to advancing innovation through the integration of biology, engineering, AI, and automation.

We thank everyone who visited Booth #509 and engaged with our team during MPS World Summit 2026. We look forward to continuing these conversations and exploring future opportunities for collaboration.